Lymphoma, Non-Hodgkin: all 2,043 studies
Page 14 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)WithdrawnNCT02657447Phase 1
- Memory-enriched CAR-T Cells Immunotherapy for B Cell LymphomaStatus unknownNCT02652910Phase 1/2
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorWithdrawnNCT02640833Phase 1
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedNCT02631044Phase 1
- Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02623920Phase 2
- Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaCompletedNCT02613598Phase 1
- 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer PatientsTerminatedNCT02602067Phase 1
- To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's LymphomaStatus unknownNCT02585947Phase 4
- Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's LymphomaCompletedNCT02581878Phase 1
- Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)WithdrawnNCT02578511Phase 1
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583
- Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT02543879Phase 1
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnNCT02538926Phase 2
- Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary LymphomaStatus unknownNCT02526823Phase 4
- Phase 1, Dose-Escalation Study of IGN002 in NHL SubjectsTerminatedNCT02519270Phase 1
- A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT02500407Phase 1/2
- GOAL: GA101 Plus Pixantrone for Relapsed Aggressive LymphomaCompletedNCT02499003Phase 2
- Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and AdolescentsCompletedNCT02488369Not applicable
- A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With CrizotinibWithdrawnNCT02487316Phase 4
- A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaStatus unknownNCT02456207Phase 2
- A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT02453087Phase 1
- Symbenda Post-Marketing Surveillance (PMS)CompletedNCT02434484
- ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's LymphomaStatus unknownNCT02431403Phase 1/2
- A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.CompletedNCT02417285Phase 1
- Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaWithdrawnNCT02378922Phase 1
- Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image QualityCompletedNCT02378337
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line TherapyStatus unknownNCT02371161Phase 2
- HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV InfectionWithdrawnNCT02343666Phase 1
- Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin LymphomaCompletedNCT02342782Phase 1
- B-Cell Hematologic Malignancy Vaccination RegistryWithdrawnNCT02298816
- Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or LymphomaCompletedNCT02293109Phase 1
- Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesCompletedNCT02290951Phase 1
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin LymphomasCompletedNCT02280785Phase 2
- Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
- Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
- COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma PatientsCompletedNCT02253420Phase 1
- Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin LymphomaCompletedNCT02221492Phase 2
- Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.CompletedNCT02206308Phase 1
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
- Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life SettingCompletedNCT02199288
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
- Copanlisib Pharmacodynamic StudyCompletedNCT02155582Phase 1
- Carfilzomib Plus Belinostat in Relapsed/Refractory NHLCompletedNCT02142530Phase 1
- Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood LymphomaWithdrawnNCT02141100Phase 1/2
- Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T LymphocytesStatus unknownNCT02134262Phase 1/2
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
- Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHLTerminatedNCT02106091Phase 1
- A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's LymphomaWithdrawnNCT02095574Phase 1
- Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT02072967
- Study of the Glutaminase Inhibitor CB-839 in Hematological TumorsCompletedNCT02071888Phase 1
- Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)Active, not recruitingNCT02050347Phase 1
- A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced NeutropeniaCompletedNCT02044276Phase 3
- Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic LymphomaTerminatedNCT02043587Phase 2
- A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With GemcitabineCompletedNCT02018874Phase 1
- Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain TumorsWithdrawnNCT02000986Not applicable
- Imaging Based Dosimetry for Individualized Internal Emitter TherapyCompletedNCT01988272
- Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood TransplantationStatus unknownNCT01983761Phase 1/2
- An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's LymphomaCompletedNCT01969695Phase 1
- A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199WithdrawnNCT01969682Phase 1
- A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199CompletedNCT01969669Phase 1
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
- Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin LymphomaCompletedNCT01958996Phase 1/2
- Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT01944943Phase 2
- Safety Study of CPX-351 in Children With Relapsed Leukemia or LymphomaCompletedNCT01943682Phase 1
- Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's LymphomaCompletedNCT01939327Phase 2
- GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01933516Phase 1
- A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's LymphomaCompletedNCT01929265Phase 2
- Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHLStatus unknownNCT01914744Phase 2
- PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic TherapyCompletedNCT01910025Phase 2
- Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
- Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesCompletedNCT01871675Phase 1
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Not applicable
- R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3BStatus unknownNCT01852435Phase 3
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2
- Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOPWithdrawnNCT01843868Not applicable
- High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaActive, not recruitingNCT01840566Phase 1
- Lenalidomide Plus Rituximab (R) in Non Follicular NHLStatus unknownNCT01830478Phase 2
- Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase TherapyActive, not recruitingNCT01829958Not applicable
- Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaActive, not recruitingNCT01815749Phase 1
- Hyper-CVAD Treatment in Lymphoblastic LymphomaStatus unknownNCT01813344
- Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT01811368Phase 2
- Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCTCompletedNCT01810120Phase 1/2
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynWithdrawnNCT01789723Phase 1
- Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin LymphomasStatus unknownNCT01786018Phase 2
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous TransplantationCompletedNCT01767714Phase 3
- Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation StudyCompletedNCT01763398
- Improve the Survival Rate of Chinese Children and Adolescents With Non-Hodgkin's LymphomaCompletedNCT01761500Phase 2
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
- Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT01746849Phase 2
- Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)TerminatedNCT01745354Phase 1